"As Dr. Sathananthan has stated, these results do not come as a surprise. Extensive preclinical
work in partnership with a large number of leading physicians has demonstrated a superior
hemodynamic result compared to commercially available products, both in native aortic stenosis
and in valve-in-valve procedures. With a rapidly growing number of degenerating AVRs, this
valve will have a dominant role in treating these patients. “"
$3b market just for ViV!!!
Ann: Exceptional Results in Second Valve-in-Valve Case, page-2
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.00 |
Change
0.000(0.00%) |
Mkt cap ! $365.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 27 | $19.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.00 | 1000 | 1 |
View Market Depth
| Last trade - 09.55am 20/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |
Day chart unavailable